In the last trading session, 2.59 million shares of the Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) were traded, and its beta was -0.00. Most recently the company’s share price was $0.24, and it changed around -$0.01 or -4.80% from the last close, which brings the market valuation of the company to $5.61M. CYCC currently trades at a discount to its 52-week high of $39.84, offering almost -16500.0% off that amount. The share price’s 52-week low was $0.23, which indicates that the current value has risen by an impressive 4.17% since then. We note from Cyclacel Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.1 million shares, with the 3-month average coming to 1.54 million.
Cyclacel Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended CYCC as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Instantly CYCC has showed a red trend with a performance of -4.80% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.3530 on recent trading dayincreased the stock’s daily price by 32.01%. The company’s shares are currently down -99.09% year-to-date, but still down -32.53% over the last five days. On the other hand, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is -85.87% down in the 30-day period. We can see from the shorts that 0.6 million shares have been sold at a short interest cover period of 0.26 day(s).
The consensus price target as assigned by Wall Street analysts is $1, which translates to bulls needing to increase their stock price by 76.0% from its current value. Analyst projections state that CYCC is forecast to be at a low of $1 and a high of $1.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 57.31%.
CYCC Dividends
Cyclacel Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Apr-02. The annual dividend yield of the stock is 1016.95 percent and its annual dividend per share was 2.40. It is important to note, however, that the 1016.95% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 61.49% of Cyclacel Pharmaceuticals Inc shares, and 6.64% of them are in the hands of institutional investors. The stock currently has a share float of 17.24%.
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of Apr 30, 2025 . The former held 3.24 shares worth $764.0, making up 0.01% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 362.0 shares worth around $85.0, which represents about 0.00% of the total shares outstanding.
